RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-15.48%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$504M
AUM Growth
+$504M
(-24%)
Cap. Flow
-$64.4M
Cap. Flow
% of AUM
-12.78%
Top 10 Holdings %
Top 10 Hldgs %
27.49%
Holding
102
New
6
Increased
45
Reduced
33
Closed
10
Top Buys
| 1 |
Biogen
BIIB
|
$9.89M |
| 2 |
Alkermes
ALKS
|
$8.44M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$5.94M |
| 4 |
Gilead Sciences
GILD
|
$5.14M |
| 5 |
Incyte
INCY
|
$4.35M |
Top Sells
| 1 |
Perrigo
PRGO
|
$10.7M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
$9.01M |
| 3 |
Medtronic
MDT
|
$8.4M |
| 4 |
HNT
HEALTH NET INC
HNT
|
$8.35M |
| 5 |
UnitedHealth
UNH
|
$7.86M |
Sector Composition
| 1 | Healthcare | 93.13% |
| 2 | Financials | 1.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Becton Dickinson
BDX
$55.3B
| $3.8M | 0.75% | 25,000 -44,000 | -64% | -$6.68M |
|
52
LivaNova
LIVN
$3.08B
| $3.78M | 0.75% | 70,000 +4,000 | +6% | +$216K |
|
|
ELGX
53
DELISTED
Endologix Inc
ELGX
| $3.64M | 0.72% | 435,000 +15,000 | +4% | +$125K |
|
|
HZNP
54
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.31M | 0.66% | 200,000 +54,000 | +37% | +$895K |
|
|
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
| $3.3M | 0.66% | +105,000 | New | +$3.3M |
|
|
ITCI
56
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.2M | 0.63% | 115,000 -11,000 | -9% | -$306K |
|
|
HTWR
57
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $3.14M | 0.62% | 100,000 +33,000 | +49% | +$1.04M |
|
58
Omnicell
OMCL
$1.5B
| $3.07M | 0.61% | 110,000 +36,000 | +49% | +$1M |
|
59
Iovance Biotherapeutics
IOVA
$807M
| $3.05M | 0.61% | 600,000 +25,000 | +4% | +$127K |
|
|
CEMP
60
DELISTED
Cempra, Inc.
CEMP
| $3M | 0.59% | 171,000 -55,000 | -24% | -$964K |
|
|
RVNC
61
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.97M | 0.59% | 170,000 -3,000 | -2% | -$52.4K |
|
62
Dynavax Technologies
DVAX
$1.19B
| $2.89M | 0.57% | 150,000 +95,000 | +173% | +$1.83M |
|
63
Insulet
PODD
$23.9B
| $2.72M | 0.54% | 82,000 -14,000 | -15% | -$464K |
|
64
Xencor
XNCR
$580M
| $2.68M | 0.53% | 200,000 +18,697 | +10% | +$251K |
|
65
Exelixis
EXEL
$10.1B
| $2.6M | 0.52% | 650,000 +190,000 | +41% | +$760K |
|
66
Ionis Pharmaceuticals
IONS
$6.79B
| $2.59M | 0.51% | 64,000 -3,000 | -4% | -$122K |
|
|
CMRX
67
DELISTED
Chimerix, Inc.
CMRX
| $2.56M | 0.51% | 500,000 +244,000 | +95% | +$1.25M |
|
68
Esperion Therapeutics
ESPR
$448M
| $2.54M | 0.5% | 150,000 +50,000 | +50% | +$846K |
|
69
Ultragenyx Pharmaceutical
RARE
$2.89B
| $2.53M | 0.5% | +40,000 | New | +$2.53M |
|
70
FibroGen
FGEN
$47.8M
| $2.43M | 0.48% | 114,000 +64,000 | +128% | +$1.36M |
|
71
Neurocrine Biosciences
NBIX
$13.8B
| $2.37M | 0.47% | +60,000 | New | +$2.37M |
|
72
MacroGenics
MGNX
$112M
| $2.25M | 0.45% | 120,000 +26,000 | +28% | +$488K |
|
|
PTLA
73
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.14M | 0.43% | 105,000 +43,000 | +69% | +$877K |
|
74
Pacira BioSciences
PCRX
$1.2B
| $2.12M | 0.42% | 40,000 +5,000 | +14% | +$265K |
|
75
Hologic
HOLX
$14.9B
| $2.07M | 0.41% | 60,000 +26,699 | +80% | +$921K |
|